文献速递头颈部肿瘤放疗

鼻咽癌患者调强放疗结束时大体肿瘤消退与血浆EB病毒DNA水平的预后价值

Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
PubMed 文献 · Radiother Oncol · 2018-10-23

回顾性分析397例非转移性鼻咽癌患者,于调强放疗前及结束时行鼻咽颈部MRI和血浆EBV DNA检测。放疗结束时大体肿瘤达完全缓解者5年局部区域无复发生存率高于非完全缓解者,血浆EBV DNA阴性者5年总生存、无失败生存及无远处转移生存均优于阳性者。多因素分析显示总肿瘤消退及推量照射是局部区域无复发生存的独立预测因素,血浆EBV DNA是总生存、无失败生存及无远处转移生存的独立预测因素。

要点

  • 调强放疗结束时总肿瘤、原发灶、转移淋巴结达完全缓解者5年局部区域无复发生存率均高于非完全缓解者(P<0.05)。
  • 持续肿瘤接受推量照射者5年局部区域无复发生存率为95.3%,未推量者为83%(P=0.034)。
  • 放疗结束时血浆EBV DNA阴性者5年总生存、无失败生存、无远处转移生存均优于阳性者(P<0.001)。

核心结论

  • 调强放疗结束时大体肿瘤消退和血浆EBV DNA水平可作为鼻咽癌患者不良预后的预测指标。
  • 持续肿瘤和/或血浆EBV DNA阳性的患者可能需要及时强化治疗。

研究设计与样本

  • 回顾性分析397例经组织学确诊的非转移性鼻咽癌患者。
  • 所有患者于治疗前及调强放疗结束时行鼻咽颈部MRI和血浆EBV DNA检测。

主要发现

  • 调强放疗结束时总肿瘤完全缓解组与非完全缓解组5年局部区域无复发生存率分别为94.9%与85.8%(P<0.05)。
  • 原发肿瘤完全缓解组与非完全缓解组5年局部无复发生存率分别为96.6%与87.3%(P<0.05)。
  • 转移淋巴结完全缓解组与非完全缓解组5年区域无复发生存率分别为98.7%与89.8%(P<0.05)。
  • 持续肿瘤接受推量照射组与未推量组5年局部区域无复发生存率分别为95.3%与83%(P=0.034)。
  • 调强放疗结束时血浆EBV DNA阴性组与阳性组5年总生存率分别为83.1%与50.3%、无失败生存率分别为81.5%与49.3%、无远处转移生存率分别为87.6%与61.5%(P<0.001)。

关键数值与推荐

  • 多因素分析显示总肿瘤消退和推量照射是局部区域无复发生存的独立预测因素。
  • 多因素分析显示血浆EBV DNA水平是总生存、无失败生存和无远处转移生存的独立预测因素。

临床怎么用

  • 原文结论指出持续肿瘤和/或血浆EBV DNA阳性的患者可能需要及时强化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess gross tumor regression and plasma Epstein-Barr virus (EBV)-DNA levels at the end of intensity-modulated radiation therapy (IMRT) and its prognostic impact on patients with nasopharyngeal carcinoma (NPC). PARTICIPANTS AND METHODS: In total, 397 patients with non-metastatic, histologically confirmed NPC were retrospectively examined. All patients underwent magnetic resonance imaging of the nasopharynx and neck, and plasma EBV DNA assays before treatment and at the end of IMRT. RESULTS: The estimated 5-year loco-regional, local and regional relapse-free survival rates for patients with complete response (CR) and non-CR of the total tumor, primary tumor and metastatic lymph nodes at the end of IMRT were 94.9% vs. 85.8%, 96.6% vs. 87.3%, and 98.7% vs. 89.8%, respectively (P < 0.05). The estimated 5-year loco-regional relapse-free survival (LRRFS) rates for patients with persistent tumor with and without boost irradiation were 95.3% vs. 83%, respectively (P = 0.034). The estimated 5-year overall survival (OS), failure-free survival (FFS) and distant metastasis-free survival (DMFS) rates for patients with negative and positive plasma EBV DNA at the end of IMRT were 83.1% vs. 50.3%, 81.5% vs. 49.3%, and 87.6% vs. 61.5%, respectively (P < 0.001). Multivariate analyses indicated that regression of the total tumor and boost irradiation was an independent predictor of LRRFS, and plasma EBV DNA levels were independent predictors of OS, FFS and DMFS. CONCLUSIONS: Gross tumor regression and plasma EBV DNA levels at the end of IMRT served as predictors of poor prognosis for patients with NPC. The patients with persistent tumor and/or positive plasma EBV DNA might require timely strengthening treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Liang SB, Zhang N, Chen DM, et al. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol. 2018. PMID: 30366725. doi:10.1016/j.radonc.2018.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。